Evidence map›Paper›PMID 39347551›Full record

ArticleActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale2024

Predicting excellent response to radioiodine in differentiated thyroid cancer using machine learning.

Ogün Bülbül, Demet Nak

Abstract read
In one paragraph

Article in Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ogün BülbülDepartment of Nuclear Medicine, Recep Tayyip Erdogan University, Faculty of Medicine, Training and Research Hospital, Rize, Turkey.
Demet NakDepartment of Nuclear Medicine, Recep Tayyip Erdogan University, Faculty of Medicine, Training and Research Hospital, Rize, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: If excellent response (ER) occurs after radioactive iodine (RAI) treatment in patients with differentiated thyroid carcinoma (DTC), the recurrence rate is low. Our study aims to predict ER at 6-24 months after RAI by using machine learning (ML) methods in which clinicopathological parameters are included in patients with DTC without distant metastasis. Methods: Treatment response of 151 patients with DTC without distant metastasis and who received RAI treatment was determined (ER/nonER). Thyroidectomy ± neck dissection pathology data, laboratory, and imaging findings before and after RAI treatment were introduced to ML models. Results: After RAI treatment, 118 patients had ER and 33 had nonER. Before RAI treatment, TgAb was positive in 29% of patients with ER and 55% of patients with nonER (p = 0.007). Eight of the ML models predicted ER with high area under the ROC curve (AUC) values (> 0.700). The model with the highest AUC value was extreme gradient boosting (AUC = 0.871), the highest accuracy shown by gradient boosting (81%). Conclusions: ML models may be used to predict ER in patients with DTC without distant metastasis.

Indexed as

Iodine RadioisotopesMachine LearningThyroid NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeIodine Radioisotopesdifferentiated thyroid cancerexcellent responsemachine learningpredictionradioactive iodine

Identifiers

PMID39347551
PMCPMC11441520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.